

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fujian Haixi Pharmaceuticals Co., Ltd.
福建海西新藥創制股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2637)

**CHANGE OF JOINT COMPANY SECRETARY,
AUTHORISED REPRESENTATIVES AND PROCESS AGENT
AND
WAIVER FROM STRICT COMPLIANCE WITH
RULES 3.28 AND 8.17 OF THE LISTING RULES**

Change of Joint Company Secretary, Authorised Representatives and Process Agent

The board (the “**Board**”) of directors (the “**Director(s)**”) of Fujian Haixi Pharmaceuticals Co., Ltd. (the “**Company**”) announces that Ms. Lam Wai Yee Sophie (“**Ms. Lam**”) has tendered her resignation as (i) a joint company secretary of the Company (“**Joint Company Secretary(ies)**”); (ii) an authorised representative under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”)(“**Authorised Representative under the Listing Rules**”); (iii) the authorised representative of the Company pursuant to Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong)(together with an Authorised Representative under the Listing Rules, the “**Authorised Representatives**”) ; and (iv) the authorised person of the Company under Rule 19A.13(2) of the Listing Rules for the acceptance of service of process and notices on behalf of the Company in Hong Kong (the “**Process Agent**”) with effect from 6 March 2026. Ms. Zhang Junhuan (“**Ms. Zhang**”) remains as one of the Joint Company Secretaries.

Ms. Lam confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company.

The Board further announces that Mr. Lau Kwok Yin (“**Mr. Lau**”) has been appointed as a Joint Company Secretary, the Authorised Representatives and the Process Agent with effect from 6 March 2026.

The biographical details of Ms. Zhang and Mr. Lau are set out as follows:

Ms. Zhang, aged 57, joined the Company in October 2021 and has served as the finance director since then and has been appointed as the secretary of the Board since October 2022. She also serves as the finance director of Haixi New Drug Creation (Fuzhou) Co., Ltd.* (海西新藥創制(福州)有限公司), a wholly-owned subsidiary of the Company since June 2022. She is primarily responsible for overseeing the financial management and the company secretarial matters of our Company.

Ms. Zhang has more than 30 years of experience in finance management. Prior to joining the Company, Ms. Zhang served as a chief accountant at Fujian Hualong Group Feedstuff Co., Ltd.* (福建省華龍集團飼料有限公司) from July 1993 to December 2002. From January 2003 to February 2004, Ms. Zhang served as a manager at planning and finance department at Taikang Life Insurance Co., Ltd. Fujian Zhangzhou Central Branch* (泰康人壽保險有限責任公司福建漳州中心支公司). She then served as a finance manager at Fujian Kewei Technical Development Co., Ltd.* (福建省科威技術發展有限公司) from March 2004 to May 2005 and a finance manager at Fuzhou Chaoda Modern Agriculture Development Co., Ltd.* (福州超大現代農業發展有限公司) (currently known as Fujian Chaoda Modern Agriculture Group Co., Ltd.* (福建超大現代農業集團有限公司)) from May 2005 to August 2007. From September 2007 to August 2011, Ms. Zhang served as a director at accounting department of Fujian Metropolis Media Co., Ltd.* (福建都市傳媒股份有限公司). And she then served as a vice president and finance director at Shenghui Logistics Group Co., Ltd.* (盛輝物流集團有限公司) from September 2011 to March 2019 and the head of finance department at Sichuan Huiyu Pharmaceutical Co., Ltd.* (四川匯宇製藥股份有限公司) (a company listed on the STAR market of Shanghai Stock Exchange, stock code: 688553) from March 2019 to October 2019.

Ms. Zhang obtained her college's degree in financial management from Wuhan University (武漢大學) in July 1993 and her bachelor's degree in accounting from Fuzhou University (福州大學) in December 2005. Ms. Zhang has qualified as a senior accountant conferred by Fujian Provincial Department of Human Resources (福建省人事廳) (currently known as Fujian Provincial Department of Human Resources and Social Security (福建省人力資源和社會保障廳) since May 2007.

Mr. Lau is a vice president of Listed Corporate Secretarial Department of SWCS Corporate Services Group (Hong Kong) Limited. He has over 15 years of experience in corporate secretarial services, finance and banking operations. He holds a bachelor's degree in business administration (accounting and finance) from The University of Hong Kong, and is a member of the Hong Kong Institute of Certified Public Accountants, a Chartered Financial Analyst charterholder, and a fellow of each of The Chartered Governance Institute and The Hong Kong Chartered Governance Institute.

Waiver from Strict Compliance with Rules 3.28 and 8.17 of the Listing Rules

Due to the above-mentioned change of a Joint Company Secretary, the Company has applied for the Stock Exchange, and the Stock Exchange has granted a new waiver (the “**New Waiver**”) from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules in relation to the eligibility of Ms. Zhang to act as a Joint Company Secretary for a period from the effective date of appointment of Mr. Lau as a Joint Company Secretary (i.e. 6 March 2026) to 19 October 2028 (the “**Remaining Waiver Period**”) on the following conditions:

- (i) Ms. Zhang must be assisted by Mr. Lau in discharging her functions as a Joint Company Secretary and in gaining the relevant experience (the “**Relevant Experience**”) as required under Rule 3.28 of the Listing Rules during the Remaining Waiver Period; and
- (ii) the New Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

Before the end of the Remaining Waiver Period, the Company must demonstrate and seek the Stock Exchange’s confirmation that Ms. Zhang, having had the benefit of Mr. Lau’s assistance during the Remaining Waiver Period, has attained the Relevant Experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary. The Stock Exchange may withdraw or change the New Waiver if the Company’s situation changes.

The Board would like to take this opportunity to express its gratitude to Ms. Lam for her contribution to the Company during her tenure of service, and to welcome Mr. Lau on his new appointment.

By order of the Board
Fujian Haixi Pharmaceuticals Co., Ltd.
Dr. Kang Xinshan
Chairman and Executive Director

Hong Kong, 6 March 2026

As at the date of this announcement, the executive Directors are Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi; the non-executive Directors are Mr. Xu Dong and Mr. Wang Xinkun; and the independent non-executive Directors are Mr. Gong Weimin, Ms. Wang Shan Shan and Ms. Pu Meiting.